Are You 18 or Older and Have Been Diagnosed With Mesothelioma or Another Solid Tumor That Has Returned or Spread After Standard Treatment?
Dr. Raffit Hassan and his team at the National Cancer Institute are conducting an early-phase clinical research trial to study a new investigational treatment called TNhYP218 CAR T cells. This investigational treatment targets a protein called mesothelin (MSLN), which is found in high levels in some cancers like mesothelioma. The study team collects immune cells (T cells); the T cells are genetically modified to target and kill tumor cells. The goal of this research study is to learn if this investigational treatment at a safe dose can potentially shrink tumors.
Who Can Join?
You may be able to take part if you:
- Are 18 or older
- Have a solid tumor, including mesothelioma, that has come back or spread after treatment
What does the study involve:
- Stay in the NIH Clinical Center in Bethesda, MD to get the investigational treatment for at least 7 days
- After you leave the NIH Clinical Center, you will return for follow-up visits
- Follow-up may include imaging scans, blood and heart tests, and a biopsy
There is no cost to participate.
The NIH Clinical Center, America's research hospital, is located in Bethesda, MD, and is accessible by the Metro Red Line (Medical Center stop).
For more information:
NIH Clinical Center Office of Patient Recruitment
1-800-411-1222
TTY users dial 7-1-1
Email: ccopr@nih.gov
Or go online:
Refer to NIH study # 002021-C
Department of Health and Human Services
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)